These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 10627857)

  • 1. The progression of chronic renal failure: a harmful quartet.
    el-Nahas AM; Tamimi N
    QJM; 1999 Aug; 92(8):421-4. PubMed ID: 10627857
    [No Abstract]   [Full Text] [Related]  

  • 2. [Management of chronic kidney disease--preventing the progression of renal disease].
    Kuroki A; Akizawa T
    Nihon Rinsho; 2008 Sep; 66(9):1735-40. PubMed ID: 18788403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New therapeutic options in renal diseases--hypotensive therapy].
    Gaciong Z
    Pol Arch Med Wewn; 2004 Oct; 112 Spec No():57-63. PubMed ID: 15669202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Ways to inhibit development of chronic renal failure].
    Tareeva IE; Kutyrina IM; Nikolaev AIu; Lifshits NL; Shvetsov MIu
    Ter Arkh; 2000; 72(6):9-14. PubMed ID: 10900641
    [No Abstract]   [Full Text] [Related]  

  • 5. [Nephroprotection: how to slow the progression of chronic renal insufficiency?].
    Hannedouche T; Krummel T; Parvez-Braun L
    Nephrol Ther; 2005 May; 1(2):135-44. PubMed ID: 16895678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of antihypertensive therapy on the course of renal failure.
    Lederle RM
    J Cardiovasc Pharmacol; 1992; 20 Suppl 6():S69-72. PubMed ID: 1283193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Possibilities of outpatient renoprotective therapy].
    Kolina IB; Stavrovskaia EV; Shilov EM
    Ter Arkh; 2005; 77(6):33-5. PubMed ID: 16078597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Which antihypertensive drugs are the most nephroprotective and why?
    Cravedi P; Ruggenenti P; Remuzzi G
    Expert Opin Pharmacother; 2010 Nov; 11(16):2651-63. PubMed ID: 20977400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arterial hypertension and proteinuria in pediatric chronic kidney disease.
    Simonetti GD; Bucher BS; Tschumi S; Lava SA; Bianchetti MG
    Minerva Pediatr; 2012 Apr; 64(2):171-82. PubMed ID: 22495191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antihypertensive therapy in chronic renal disease: a place for sympathicolytic agents?
    Laverman GD; Remuzzi G
    J Hypertens; 2003 Sep; 21(9):1625-6. PubMed ID: 12923391
    [No Abstract]   [Full Text] [Related]  

  • 11. [The influence of antihypertensive treatment on progression of chronic nepropathy].
    Petersen LJ; Ladefoged SD; Jensen HA
    Ugeskr Laeger; 1997 Jul; 159(31):4745-51. PubMed ID: 9265325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Sequelae of hypertenson: kidney disease].
    Hörl WH
    Internist (Berl); 2006 Mar; 47(3):226, 228-32. PubMed ID: 16470357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Difficult therapy in patients with renal failure. What protects, what damages the kidneys?].
    Stiefelhagen P
    MMW Fortschr Med; 2005 Apr; 147(16):4-6. PubMed ID: 16392389
    [No Abstract]   [Full Text] [Related]  

  • 14. Identifying and slowing progressive chronic renal failure.
    Curtis B; Barrett BJ; Levin A
    Can Fam Physician; 2001 Dec; 47():2512-8. PubMed ID: 11785282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What have we learned from clinical trials on prevention?
    Pellicano R; Kerr PG; Atkins RC
    Kidney Int Suppl; 2005 Apr; (94):S101-6. PubMed ID: 15752224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with chronic kidney disease.
    Kolesnyk I; Struijk DG; Dekker FW; Krediet RT
    Neth J Med; 2010 Jan; 68(1):15-23. PubMed ID: 20103817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interim evidence of the renoprotective effect of the angiotensin II receptor antagonist losartan versus the calcium channel blocker amlodipine in patients with chronic kidney disease and hypertension: a report of the Japanese Losartan Therapy Intended for Global Renal Protection in Hypertensive Patients (JLIGHT) Study.
    Iino Y; Hayashi M; Kawamura T; Shiigai T; Tomino Y; Yamada K; Kitajima T; Ideura T; Koyama A; Sugisaki T; Suzuki H; Umemura S; Kawaguchi Y; Uchida S; Kuwahara M; Yamazaki T;
    Clin Exp Nephrol; 2003 Sep; 7(3):221-30. PubMed ID: 14586719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lessons from large interventional trials on antihypertensive therapy in chronic renal disease.
    Maschio G; Marcantoni C; Bernich P
    Nephrol Dial Transplant; 2002; 17 Suppl 11():47-9. PubMed ID: 12386259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addition of aliskiren to olmesartan ameliorates tubular injury in chronic kidney disease patients partly by reducing proteinuria.
    Nakamura T; Sato E; Amaha M; Kawagoe Y; Maeda S; Yamagishi S
    J Renin Angiotensin Aldosterone Syst; 2012 Mar; 13(1):122-7. PubMed ID: 21946392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of antihypertensive drugs on the progress of renal failure in hyperlipidemic Imai rats.
    Sakemi T; Baba N
    Nephron; 1993; 63(3):323-9. PubMed ID: 8446271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.